Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 8906 results

  1. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 February 2027

    NICE guideline
    In development

  2. Pharmalgen for the treatment of bee and wasp venom allergy

    In development Reference number: GID-TA11898 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Seladelpar for previously treated primary biliary cholangitis [ID6429]

    In development Reference number: GID-TA11540 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  5. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]

    Awaiting development Reference number: GID-TA11908 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Nivolumab + Brentuximab vedotin for Hodgkin lymphoma [ID6691]

    Awaiting development Reference number: GID-TA11909 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  15 July 2026

    NICE guideline
    In development

  9. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 23 February 2026.

    NICE guideline
    In consultation

  10. Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]

    Awaiting development Reference number: GID-TA11910 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    Awaiting development Reference number: GID-TA11052 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237

    In development Reference number: GID-TA10239 Expected publication date:  06 August 2026

    Technology appraisal guidance
    In development

  14. Artificial intelligence (AI) technologies to help detect prostate cancer on multiparametric (mp) MRI

    In development Reference number: GID-HTE10089 Expected publication date: TBC

    Health technology evaluations
    In development

  15. Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]

    Awaiting development Reference number: GID-TA11917 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development